• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Research uncovers life-saving benefits in the battle against viruses

, 26 August 2020/in E-News /by 3wmedia

At-risk patients, such as those with HIV or transplant recipients, could benefit from potentially life-saving study carried out by a University of Surrey led group of international researchers.

The research, led by Professor Vince Emery, Senior Vice-President (Global Strategy and Engagement) and Professor of Translational Virology at the University of Surrey, has developed a model that will provide vital insight into how best to help patients with Cytomegalovirus (CMV) infection, particularly those who have undergone organ transplantation.

CMV can be serious if the patient’s immune system is not fully functioning, as in transplant patients on immune-suppressant drugs, or for HIV patients in the advanced stages of AIDS. In these cases, CMV can cause major health problems, affecting a range of organs and contributing to early death, which obviously makes it vital to understand how to control the virus.

The mainstay of therapy for CMV has been an antiviral drug called Ganciclovir, which mimics the building blocks of DNA and stops the virus from replicating.

In the current study, the researchers used information from a large clinical trial of Ganciclovir for the treatment of CMV disease in patients who had undergone solid organ transplantation, to assess the patterns of viral responses seen following therapy.

This is the first time that a comprehensive model has been developed which explains the full range of post-therapy virus decline patterns. It provides vital insight into how to best help patients with CMV infection, especially after solid organ transplants and is potentially extendable to stem cell transplant patients.

The researchers have identified four unique patterns of response and have then used this to develop a sophisticated mathematical model which can accurately account for these patterns of decline.

The researchers’ work also benefits patients by leading the way forward to personalised medicine, and will make it possible to predict the likely duration of therapy needed for a patient with CMV infection to clear the virus.

Professor Emery said: ‘I am very proud to have led this vital research, as it will improve the health and quality of life of patients with CMV infection. CMV is a member of the herpes virus family and related to the virus that causes cold sores; these viruses are widespread and usually harmless.

‘But in some at risk cases, such as when the patients’ immune system is not fully functioning, it could mean the difference between life and death.

University of Surrey www.surrey.ac.uk/mediacentre/press/2017/research-uncovers-life-saving-benefits-battle-against-viruses

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:29Research uncovers life-saving benefits in the battle against viruses

Immunotherapy kinder than chemotherapy for patients with head and neck cancer

, 26 August 2020/in E-News /by 3wmedia

The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer – easing many of the negative effects of the disease on patients’ quality of life.
Both head and neck cancer and the treatment for it can have a huge impact on patients – affecting their speech, breathing, eating and drinking, facial appearance, and general wellbeing.
All of this can cause substantial psychological, as well as physical, distress.
But patients taking part in a major phase III clinical trial – led by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust – reported that nivolumab helped them maintain a better quality of life for longer.
By contrast, the same study also found that people treated with standard chemotherapies docetaxel, methotrexate or cetuximab reported a decline in quality of life from the start of treatment.
Last year, the clinical trial of 361 patients found that nivolumab – which sparks the immune system into action against cancers – greatly increased survival for people with recurrent or metastatic head and neck cancer.
But the drug was initially rejected by NICE in April this year and is currently under consultation before a final decision is due.
The new results add to the growing body of evidence that immunotherapy can be a smarter, kinder treatment for people with cancer.
In the latest study, 129 patients on the trial filled in questionnaires about their quality of life – covering physical symptoms, mental health and general wellbeing.
While patients on chemotherapy judged their quality of life to be lower at nine and 15 weeks into the trial, patients on nivolumab gave consistently better ratings throughout.
After nine weeks, patients given nivolumab reported that they were doing better than their counterparts on other treatments for a range of symptoms, including pain, sensory problems, appetite loss, tiredness and breathing problems.
After 15 weeks, the list of beneficial effects was even longer, with patients taking nivolumab being less badly affected by nausea, insomnia and weight loss.

Institute of Cancer Research
www.icr.ac.uk/news-archive/immunotherapy-kinder-than-chemotherapy-for-patients-with-head-and-neck-cancer

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:15Immunotherapy kinder than chemotherapy for patients with head and neck cancer

Use of stereotactic radiation in early-stage lung cancer

, 26 August 2020/in E-News /by 3wmedia

The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer. While SBRT is the current standard of care for peripherally located tumours in patients who cannot undergo surgery, the new guideline addresses the appropriateness of SBRT for medically inoperable patients with high-risk clinical scenarios requiring curative focused therapy. The guideline also reviews the role of SBRT for centrally located tumours because of their unique risks compared to peripheral tumours.
SBRT is an advanced type of external beam radiation therapy that uses sophisticated planning techniques to deliver an extremely high dose of radiation very precisely to a tumour. This high degree of precision makes SBRT notably effective at sparing healthy tissues surrounding the tumour, which is particularly important with lung tumours. For patients who are not fit enough for early-stage lung cancer surgery, SBRT presents a viable option for curative-intent treatment since it provides excellent outcomes with low toxicity. Compared to conventional external beam radiation therapy, which is delivered over several weeks, SBRT is typically administered in five or fewer treatment sessions, or fractions.
Drawing on data from retrospective and prospective studies and the available randomized clinical trials, the guideline provides evidence-based recommendations regarding the appropriate use of SBRT for early-stage non-small cell lung cancer (NSCLC). The principal goal of the guideline was to address SBRT for patients unable to tolerate surgery who require customization of SBRT in high-risk clinical scenarios, such as for salvage therapy after previous surgery or radiation therapy, for tumours invading the chest wall or for very large tumours. The guideline also details principles of SBRT directed toward centrally located lung tumours, since treating these tumours carries unique and significant risks when compared to treatment directed at peripherally located tumours. Additionally, although the focus of the guideline was the inoperable patient, the appropriateness of SBRT in the operable patient also was addressed, since it is an area of debate and controversy.

ecancernews
ecancer.org/news/11751-astro-issues-guideline-for-use-of-stereotactic-radiation-in-early-stage-lung-cancer.php

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:22Use of stereotactic radiation in early-stage lung cancer

Triple-threat cancer-fighting polymer capsules for guided drug delivery

, 26 August 2020/in E-News /by 3wmedia

Chemists at the University of Alabama at Birmingham have designed triple-threat cancer-fighting polymer capsules that bring the promise of guided drug delivery closer to preclinical testing.

These multilayer capsules show three traits that have been difficult to achieve in a single entity. They have good imaging contrast that allows detection with low-power ultrasound, they can stably and efficiently encapsulate the cancer drug doxorubicin, and both a low- and higher-power dose of ultrasound can trigger the release of that cargo.

These three features create a guided drug delivery system to target solid tumours. Therapeutic efficacy can be further improved through surface modifications to boost targeting capabilities. Diagnostic low-power ultrasound then could visualize the nanocapsules as they concentrated in a tumour, and therapeutic higher-dose ultrasound would release the drug at ground zero, sparing the rest of the body from dose-limiting toxicity.

This precise control of when and where doxorubicin or other cancer drugs are released could offer a non-invasive alternative to cancer surgery or systemic chemotherapy, the UAB researchers report.

‘We envision an entirely different approach to treating solid human tumours of numerous pathologic subtypes, including common metastatic malignancies such as breast, melanoma, colon, prostate and lung, utilizing these capsules as a delivery platform,’ said Eugenia Kharlampieva, Ph.D., an associate professor in the Department of Chemistry, UAB College of Arts and Sciences. ‘These capsules can protect encapsulated therapeutics from degradation or clearance prior to reaching the target and have ultrasound contrast as a means of visualizing the drug release. They can release their encapsulated drug cargo in specific locations via externally applied ultrasound exposure.’

Kharlampieva – who creates her novel ‘smart’ particles while working at the intersection of polymer chemistry, nanotechnology and biomedical science – says there is an urgent, and so far unmet, need for such an easily fabricated, guided drug delivery system.

University of Alabama at Birmingham www.uab.edu/news/innovation/item/8162-uab-creates-triple-threat-cancer-fighting-polymer-capsules-for-guided-drug-delivery

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:31Triple-threat cancer-fighting polymer capsules for guided drug delivery

New MRI method aids long-term concussion prognosis

, 26 August 2020/in E-News /by 3wmedia

For concussion sufferers, even those who never lost consciousness, physicians may now be able to predict early on who is more likely to continue experiencing symptoms months or years after the head-jarring event, using a new non-invasive magnetic resonance imaging (MRI) method devised by a consortium of researchers led by UC San Francisco scientists.
In their new study the researchers used functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.
The study revealed tell-tale patterns of brain activity that, six months later, were associated with worse performance on behavioural and cognitive tests and were different from patterns seen in healthy control subjects.
The fMRI method and analysis developed for the study highlighted abnormal patterns of brain activity that pointed to a higher risk for long-term, post-concussive symptoms, even among the 44 study participants who had no evidence of bleeding or bruising in the brain in the immediate aftermath of brain trauma on computed tomography (CT) or ordinary MRI scans.
“This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,” said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study. “We may be able to use this information to help guide treatment decisions and counselling of patients early on, when it may be more effective.”
Only subjects who had lost consciousness for less than 30 minutes were eligible for the study, and many study subjects never lost consciousness during their injury.

University of California – San Franciscohttp://tinyurl.com/yc6cfxrn

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:17New MRI method aids long-term concussion prognosis

‘Smart contact lens sensor’ for diabetic and glaucoma diagnosis

, 26 August 2020/in E-News /by 3wmedia

A recent study, affiliated with UNIST has proposed the possibility of in situ human health monitoring simply by wearing a contact lens with built-in wireless smart sensors.

This study has been jointly conducted by Professor Jang-Ung Park of Materials Science and Engineering, Professor Chang Young Lee of Life Science, and Professor Franklin Bien of Electrical and Computer Engineering at UNIST in collaboration with Professor Hong Kyun Kim of Ophthalmology and Professor Kwi-Hyun Bae of Internal Medicine at Kyungpook National University (KNU).

In the study, the research team unveiled a smart contact lens sensor that could help monitor biomarkers for intraocular pressure (IOP), diabetes mellitus, and other health conditions. The research team expects that this research breakthrough could lead to the development of biosensors capable of detecting and treating various human diseases, and used as a component of next-generation smart contact lens-related electronic devices.

Diabetes is the most common cause of high blood sugar levels. Hyperglycaemia is a condition in which an excessive amount of glucose circulates in the blood plasma. If this condition persists for more than two hours, a patient will be diagnosed with diabetes.

Since blood sugar can be measured with tears, many attempts have been made to monitor diabetes with contact lenses. Despite numerous studies in the last several decades, the biggest drawback with conventional smart contact lenses was thought to be poor wearability. The electrodes used in existing smart contact lenses are opaque, and therefore obscure the view when wearing it. Moreover, because they lens-shaped firm plastic material, many people complain of comfort issues with contact lens wear which made wearing them impossible.

Professor Park and his research team solved these issues by developing a sensor based on transparent and flexible materials. Their new smart contact lens sensors use electrodes made of highly stretchable and transparent graphene sheets and metal nanowires.

Using this sensor, patients with diabetes and glaucoma may one day be able to self-monitor blood glucose levels and eye pressure. Through the embedded wireless antenna in the contact lens sensor, patients can also transmit their health information, which allows real-time monitoring of their health conditions, as well. In addition, because the system uses wireless antenna to read sensor information, no separate power source, like battery is required for the smart contact lens sensors.

Intraocular pressure measurement can be achieved using the dielectric layers. The dielectric layer is an electrically non-conductive layer, characterized by polarity that divides both positive and negative charges. The thickness of this layer changes from thinning as the intraocular pressure increases, to thickening as the intraocular pressure decreases. The IOP sensor, embedded in the contact lenses senses this and transmits the information to the wireless antenna.

According to the research team, their newly-developed smart lenses with built-in pressure-sensing and glucose-monitoring sensors could still detect blood glucose and IOP despite the deformation of the contact lenses. The sensor characteristics were also maintained even when exposed to various substances in human tears.

UNIST news.unist.ac.kr/smart-contact-lens-sensor-for-diabetic-and-glaucoma-diagnosis/

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:26‘Smart contact lens sensor’ for diabetic and glaucoma diagnosis

New nano approach could cut dose of leading HIV treatment in half

, 26 August 2020/in E-News /by 3wmedia

Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.

The healthy volunteer trial, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, and in collaboration with the St Stephen’s AIDS Trust at the Chelsea & Westminster Hospital in London, examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials that are the first to use orally dosed nanomedicine to enable HIV therapy optimisation.

Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. By developing smaller pills that are better for patients and less expensive to manufacture, this evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.

Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.

Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.

The trial results confirmed the potential for a 50 percent dose reduction while maintaining therapeutic exposure, using a novel approach to formulation of two drugs: efavirenz (EFV) and, lopinavir (LPV). EFV is the current WHO-recommended preferred regimen, with 70percent of adult patients on first-line taking an EFV-based HIV treatment regimen in low- and middle-income countries.

University of Liverpool news.liverpool.ac.uk/2017/02/17/new-nano-approach-to-hiv-therapy-presented-at-leading-conference/

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:34New nano approach could cut dose of leading HIV treatment in half

Hospitals that spend more on emergency care yield better outcomes

, 26 August 2020/in E-News /by 3wmedia

Hospitals that spend more on initial care following patient emergencies have better outcomes than hospitals that spend less at first and rely more on additional forms of long-term care, according to a new study co-authored by MIT economists.
More specifically, hospitals that invest more in inpatient care yield better results, per dollar spent, than those that assign relatively more patients to skilled nursing facilities upon discharge. Other things being equal, allocating a higher percentage of overall health care expenses to a hospital’s inpatient treatment is consistent with lower mortality rates among elderly Medicare recipients.
“We find that patients who go to hospitals that rely more on skilled nursing facilities after discharge, as opposed to getting them healthy enough to return home, are substantially less likely to survive over the following year,” says Joseph Doyle, the Erwin H. Schell Professor of Management at the MIT Sloan School of Management and co-author of a paper detailing the study.
Conversely, Doyle adds: “What types of hospitals are low-cost and have good outcomes? They spend a lot when you’re there, initially, but a lot less [after] you leave the hospital.”
The co-authors are Doyle; John A. Graves, an assistant professor at Vanderbilt University; and Jonathan Gruber, the Ford Professor of Economics at MIT.
The study aims, in part, to address the fact that the U.S. spends about 40 percent more on health care per capita than the next highest-spending country in the Organisation for Economic Co-operation and Development (OECD), a group of 35 major nations — a figure that leads many to wonder whether there are significant ineffeciencies in U.S. health care spending.
In devising their experiment, the researchers took advantage of ambulance company practices that essentially provided a randomized group of patients to study, making it possible to compare outcomes at different hospitals.
The study uses Medicare claims data for hospital admissions from 2002 to 2011, focusing on patients who were at least 66 years old, and tracking their one-year mortality statistics. The study’s final database comprised 1,575,273 patients.
In many parts of the U.S., multiple ambulance companies cover a given area, and their assignment to patients is essentially random; the first available company will take a patient. However, ambulance companies often have agreements or preferences concerning which hospitals they deliver patients to. That means the ambulance companies are essentially delivering a randomized set of people to certain hospitals.
For this reason, the study avoids a basic problem in comparing hospital outcomes — that patients admitted to one hospital may be significantly less healthy, on average, than the patients admitted to another. All told, there are about 2,500 ambulance companies and about 3,000 hospitals in the data set.
The average 90-day spending on patients in the study is almost $27,500; for every additional increase in spending of roughly $8,500, the researchers found a reduction in mortality risk of about 2 percentage points. However, the study finds about a 5 percentage-point increase in mortality at hospitals that have relatively high rates of spending on “downstream” nursing facilities.
“We see this as a potentially novel quality measure for hospitals,” Doyle says. “Hospitals that have that profile where they send patients to skilled nursing facilities have higher spending downstream, and they have worse outcomes.”
The paper is one of a series of studies by Doyle and his colleagues which use the random assignment of patients to hospitals, due to ambulance-dispatch practices, in order to evaluate hospital effectiveness. In a previous study more strictly focused on the intensity of emergency care treatments, Doyle also found that higher spending leads to better outcomes.

MIT
news.mit.edu/2017/hospitals-spend-more-emergency-care-yield-better-outcomes-0710

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:12Hospitals that spend more on emergency care yield better outcomes

Brain-computer interface allows completely locked-in people to communicate

, 26 August 2020/in E-News /by 3wmedia

A brain-computer interface that can decipher the thoughts of people who are unable to communicate could revolutionize the lives of those living with complete locked-in syndrome. Counter to expectations, the participants in the study reported being ‘happy’ despite their condition.
In the trial, people with complete locked-in syndrome, who were incapable of even moving their eyes to communicate, were able to respond ‘yes’ or ‘no’ via thought to spoken questions. A non-invasive brain-computer interface (BCI) detected their responses by measuring changes in blood oxygen levels in the brain.
The results overturn previous theories that people with complete locked-in syndrome lack the goal_directed thinking necessary to use a brain computer interface and are therefore incapable of communication.
Extensive investigations were carried out in four people with ALS (amyotrophic lateral sclerosis) – a progressive motor neuron disease that leads to complete destruction of the part of the nervous system responsible for movement.
The researchers asked personal questions with known answers and open questions that needed ‘yes’ or ‘no’ answers including: ‘Your husband’s name is Joachim?’ and ‘Are you happy?’. They found the questions elicited correct responses seven times out of ten.
Professor Niels Birbaumer, a neuroscientist at the Wyss Center for Bio and Neuroengineering in Geneva, senior author of the paper said: ‘The striking results overturn my own theory that people with complete locked-in syndrome are not capable of communication. We found that all four people we tested were able to answer the personal questions we asked them, using their thoughts alone. If we can replicate this study in more patients I believe we could restore useful communication in completely locked-in states for people with motor neuron diseases.’
The question ‘Are you happy?’ resulted in a consistent ‘Yes’ response from the four people, repeated over weeks of questioning.
Professor Birbaumer said: ‘We were initially surprised at the positive responses when we questioned the four completely locked-in participants about their quality of life. All four had accepted artificial ventilation in order to sustain their life when breathing became impossible so, in a sense, they had already chosen to live. What we observed was as long as they received satisfactory care at home, they found their quality of life acceptable. It is for this reason, if we could make this technique widely clinically available, it would have a huge impact on the day-to-day life of people with complete locked-in syndrome’.

Wyss Center http://tinyurl.com/j7plj5n

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:24Brain-computer interface allows completely locked-in people to communicate

New consensus statement for treatment of empyema

, 26 August 2020/in E-News /by 3wmedia

Although treatable, empyema is a potentially deadly accumulation of pus around the lungs, occurring most commonly as a complication of pneumonia. To better manage this disease in the face of rising demand for treatment, the American Association for Thoracic Surgery (AATS) Guidelines Committee called for the formation of the Empyema Management Guidelines Working Group. Comprised of experts from a variety of disciplines including thoracic surgery, pulmonary and critical care medicine, infectious diseases, and interventional radiology, the group was tasked with analysing the latest literature about empyema and issuing new evidence-based clinical guidelines. The resulting Consensus Statement is published in the www.jtcvsonline.org/.

In the United States, around 1 million patients each year are hospitalised with pneumonia. Of this group, around 20percent to 40percent develop a parapneumonic effusion and 5percent-10percent of these will progress to empyema. Patients who experience empyema face discouraging odds: approximately 15percent of them will die and 30percent will require surgical draining to clear the infection. While occurrences of empyema dropped dramatically during first half of the 20th century thanks to improved antibiotic regimens, that trend changed in the 1990s. Now, doctors are seeing more cases, making empyema an even more relevant subject for clinical study.

‘The management of empyema has historically varied significantly from hospital to hospital and across the many different medical specialists who may care for patients with this disease,’ remarked lead author K. Robert Shen, MD, Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN. ‘These new guidelines formulated by the AATS are important because they represent an attempt to develop recommendations that are based upon the best available current scientific evidence.

The guidelines encompass empyema presentation, diagnosis, and treatment presenting a comprehensive strategy for doctors treating empyema patients. There are several top-level takeaways from their findings:

Patients with pneumonia that fail to respond to established antibiotic therapy or unexplained sepsis should always be evaluated for a possible pleural effusion. If either a parapneumonic effusion or empyema is found, patients should undergo immediate treatment.
According to the group’s findings, surgery remains the most effective method for management of most patients with empyema despite advances in radiologic imaging, antibiotics, and other medications that have made it possible to treat without undergoing a surgical procedure.
Management of paediatric empyema differs significantly from treatment in adults. Investigators acknowledge there is currently disagreement about the best treatment protocols for children with empyema. After a comprehensive analysis of current literature, the group issued a recommendation that pediatric patients should initially be treated with a tube thoracostomy with or without the subsequent instillation of fibrinolytic agents.

As empyema cases become increasingly common, investigators hope these guidelines can help make diagnosis and treatment protocols more uniform across the country to help offer patients the best care possible. ‘Despite the widespread use of antibiotics and availability of pneumococcal vaccines, empyema remains the most common complication of pneumonia and an important cause of morbidity and mortality worldwide,’ concluded Dr. Shen. ‘It is hoped that these guidelines will provide clinicians who care for pneumonia patients with practical guidelines on the best way to treat their patients who develop empyema.’

EurekAlert www.eurekalert.org/pub_releases/2017-04/aaft-ain042017.php

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:37:112020-08-26 14:37:29New consensus statement for treatment of empyema
Page 186 of 231«‹184185186187188›»

Latest issue of International Hospital

April 2024

1 July 2025

BMJ investigation reveals AstraZeneca’s billion-dollar heart drug built on flawed data

27 June 2025

Scientists launch world first project to create synthetic human genome with £10mn Wellcome funding

27 June 2025

GE HealthCare advances precision imaging with MIM Encore platform

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription